Matches in Wikidata for { <http://www.wikidata.org/entity/Q80564535> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q80564535 description "article scientifique publié en 2007" @default.
- Q80564535 description "artículu científicu espublizáu en xunetu de 2007" @default.
- Q80564535 description "scientific article published on 03 July 2007" @default.
- Q80564535 description "wetenschappelijk artikel" @default.
- Q80564535 description "наукова стаття, опублікована в липні 2007" @default.
- Q80564535 name "Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo" @default.
- Q80564535 name "Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo" @default.
- Q80564535 type Item @default.
- Q80564535 label "Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo" @default.
- Q80564535 label "Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo" @default.
- Q80564535 prefLabel "Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo" @default.
- Q80564535 prefLabel "Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo" @default.
- Q80564535 P1433 Q80564535-5773B93A-EA5E-47EE-A114-18B3E944899B @default.
- Q80564535 P1476 Q80564535-31E146DC-6767-4556-9B90-52B6661B315B @default.
- Q80564535 P2093 Q80564535-A0B34C09-95F6-440B-815E-67F7FE5992F0 @default.
- Q80564535 P2093 Q80564535-A8825580-DAAA-422E-8337-F19BA7A91899 @default.
- Q80564535 P2093 Q80564535-AD012B2C-7918-4B7E-A282-AF8C24772793 @default.
- Q80564535 P2093 Q80564535-D342F188-FDFD-4836-B167-8E02DEB7DF7B @default.
- Q80564535 P2093 Q80564535-EB89BDFF-4B24-4701-9AD0-05FC83FB4BB1 @default.
- Q80564535 P304 Q80564535-86C14703-66DC-44D9-BEA7-B4550FEF3347 @default.
- Q80564535 P31 Q80564535-1BCE09DD-A390-4E07-B7B1-580CC8D125A4 @default.
- Q80564535 P356 Q80564535-FEF9E98F-5193-4866-BFFC-75467D76C6CB @default.
- Q80564535 P407 Q80564535-551E6F38-9B28-4D16-B2C1-5C075451CCCF @default.
- Q80564535 P433 Q80564535-63DB8B2C-AC75-4F2E-9299-89E91BBF342B @default.
- Q80564535 P478 Q80564535-49CC2515-0899-49C9-AFAA-C40AFABB1E4C @default.
- Q80564535 P577 Q80564535-BE28351C-762B-4079-8ACB-20688A15B77F @default.
- Q80564535 P698 Q80564535-722166D3-80D2-4D07-BE1B-1F2642335CD2 @default.
- Q80564535 P921 Q80564535-5110742B-FE22-4755-A85D-9EA4C1B7ADB7 @default.
- Q80564535 P356 JRR.07014 @default.
- Q80564535 P698 17609586 @default.
- Q80564535 P1433 Q2330802 @default.
- Q80564535 P1476 "Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo" @default.
- Q80564535 P2093 "A J Colquhoun" @default.
- Q80564535 P2093 "E Tulchinsky" @default.
- Q80564535 P2093 "J K Mellon" @default.
- Q80564535 P2093 "L A Mchugh" @default.
- Q80564535 P2093 "M Kriajevska" @default.
- Q80564535 P304 "351-360" @default.
- Q80564535 P31 Q13442814 @default.
- Q80564535 P356 "10.1269/JRR.07014" @default.
- Q80564535 P407 Q1860 @default.
- Q80564535 P433 "5" @default.
- Q80564535 P478 "48" @default.
- Q80564535 P577 "2007-07-03T00:00:00Z" @default.
- Q80564535 P698 "17609586" @default.
- Q80564535 P921 Q504775 @default.